Rapamycin: in vitro profile of a new immunosuppressive macrolide.
about
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingMultiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Vascular smooth muscle cell proliferation in restenosis.Introductory remarks: immunosuppressive and immunomodulating drugs, where and how do they act?Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
P2860
Rapamycin: in vitro profile of a new immunosuppressive macrolide.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Rapamycin: in vitro profile of a new immunosuppressive macrolide.
@en
type
label
Rapamycin: in vitro profile of a new immunosuppressive macrolide.
@en
prefLabel
Rapamycin: in vitro profile of a new immunosuppressive macrolide.
@en
P2860
P1476
Rapamycin: in vitro profile of a new immunosuppressive macrolide.
@en
P2093
Bansbach CC
P2860
P356
10.1111/J.1749-6632.1993.TB35852.X
P407
P577
1993-06-01T00:00:00Z